Pre-registration Exam Paper 1: Applied Pharmacy Practice within a Legal Framework

Correct: Under the Human Medicines Regulations 2012, an entry for a private prescription for a Prescription Only Medicine (POM) must be made in the POM register on the day of supply or the next following day. This entry must include the date of supply, the date on the prescription, the name, quantity, formulation and strength of the medicine, and the name and address of both the prescriber and the patient. Crucially, oral contraceptives are legally exempt from the requirement to be recorded in the POM register, and Schedule 2 controlled drugs are recorded in the CD register instead.

Incorrect: Recording all private prescriptions including Schedule 2 Controlled Drugs in the POM register is incorrect because Schedule 2 and most Schedule 3 substances are legally required to be entered into the Controlled Drugs Register; if an entry is made there, a POM register entry is not legally required. Requiring the patient’s date of birth and the prescriber’s professional registration number as mandatory legal entries is incorrect, as these specific details are not statutory requirements for a POM register entry under the Human Medicines Regulations 2012. Retaining the POM register for five years is incorrect because the statutory requirement is to retain the register for two years from the date of the last entry.

Takeaway: Legal compliance for the POM register requires timely, accurate entries for private prescriptions while correctly applying exemptions for oral contraceptives and medications recorded in the Controlled Drugs Register.

Correct: Under the Human Medicines (Amendment) (No. 3) Regulations 2015, pharmacies operating as commissioned drug treatment services are permitted to supply naloxone to any individual for the purpose of saving a life in an emergency. This legal framework allows the supply to be made without a prescription, Patient Group Direction (PGD), or Patient Specific Direction (PSD), provided the supply is made by the service in the course of providing drug treatment and the recipient is provided with adequate training on how to administer the naloxone.

Incorrect: Restricting the supply only to the individual at risk of overdose is a common misconception that fails to account for the legal provision allowing supply to carers, family members, or peers who may be the ones actually administering the drug during an emergency. Suggesting that a Patient Group Direction (PGD) is the only legal mechanism for this supply is incorrect because the 2015 amendment created a specific statutory exemption for drug services that operates independently of PGD requirements. Stating that only registered healthcare professionals can facilitate the supply is inaccurate, as the legislation allows any staff member within the commissioned drug treatment service to provide the kit, provided they are competent and the service requirements are met. Requiring a signed requisition from a medical practitioner is a regulatory hurdle that does not apply to the supply of naloxone under these specific drug treatment service exemptions.

Takeaway: Pharmacies commissioned as drug treatment services can legally supply naloxone to any person for emergency use without a prescription or PGD, provided appropriate training is delivered to the recipient.

Correct: Under the Mental Capacity Act 2005 and NICE guideline SC1 (Managing medicines in care homes), covert administration is only permissible after a formal assessment confirms the resident lacks the mental capacity to make decisions about their treatment. A multidisciplinary team (MDT) meeting involving the prescriber, care home staff, and family or an advocate must determine that covert administration is in the person’s best interests. A clear management plan must be documented in the resident’s records, detailing the method of administration and specifying a date for regular review to ensure the practice remains necessary and proportionate.

Incorrect: One approach suggests that clinical necessity and the life-sustaining nature of the medication are sufficient for the GP and pharmacist to authorize covert administration; however, this fails to meet the legal requirement for a formal capacity assessment and a multidisciplinary best interests process. Another approach focuses on obtaining consent from a legal representative or next of kin and checking medication stability; while these are important factors, they do not replace the mandatory MDT framework and the requirement for a documented management plan. A third approach suggests implementing covert administration as an interim measure before a capacity assessment is completed; this is legally non-compliant as the lack of capacity must be established under the Mental Capacity Act before such an intervention can be legally justified.

Takeaway: Covert administration in the UK requires a formal capacity assessment, a multidisciplinary best interests decision, and a documented management plan with regular reviews to comply with the Mental Capacity Act 2005.

Correct: Under the Misuse of Drugs (Safe Custody) Regulations 1973, specific Schedule 3 controlled drugs are legally required to be stored in a locked cabinet that meets the regulatory standards for security. These specific drugs include Temazepam, Buprenorphine, Diethylpropion, and Flunitrazepam. Other Schedule 3 drugs, such as Tramadol, Gabapentin, Pregabalin, and Phenobarbital, are legally exempt from these safe custody requirements, although they must still be stored in a way that prevents unauthorized access within the pharmacy.

Incorrect: The approach suggesting that all Schedule 3 controlled drugs must be stored in the CD cabinet is incorrect because the 1973 Regulations provide specific exemptions for the majority of drugs in this schedule, such as Tramadol and Midazolam. The approach stating that all Schedule 3 drugs are exempt from safe custody requirements is incorrect because it fails to recognize the legal mandate for high-risk substances like Temazepam and Buprenorphine. The approach requiring safe custody for Phenobarbital and Midazolam while exempting Temazepam is legally inaccurate, as Temazepam is one of the primary Schedule 3 drugs that must be kept in a locked cabinet, whereas Phenobarbital and Midazolam are legally exempt from safe custody.

Takeaway: Pharmacists must distinguish between Schedule 3 drugs that require safe custody, such as Temazepam and Buprenorphine, and those that are exempt, such as Tramadol and Gabapentin.

Correct: Under the Human Medicines Regulations 2012, there is a strict legal prohibition regarding the simultaneous sale of pseudoephedrine and ephedrine. It is unlawful to sell or supply any product or combination of products that contain pseudoephedrine and any product or combination of products that contain ephedrine in the same transaction. This restriction exists independently of the specific milligram limits (720mg for pseudoephedrine and 180mg for ephedrine) that apply to those substances when sold individually.

Incorrect: One approach suggests that the sale is permissible if the combined total of both substances stays under the 720mg threshold, but this is incorrect as the law prohibits the co-supply of these two different substances regardless of the total weight. Another approach incorrectly identifies ephedrine nasal drops as being restricted to Prescription Only Medicine (POM) status; however, ephedrine is available as a Pharmacy (P) medicine in specific concentrations and pack sizes for nasal use. A third approach suggests that the 720mg limit for pseudoephedrine is exceeded based on salt-to-base calculations, but the legal limit of 720mg applies to the salt form (pseudoephedrine hydrochloride) as stated on the product packaging.

Takeaway: It is a legal requirement in the UK to refuse the sale of any combination of pseudoephedrine and ephedrine products within a single transaction.

Correct: Ensuring the prescription includes the Royal College of Veterinary Surgeons (RCVS) registration number and the specific declaration that the item is for an animal or herd under the prescriber’s care is the legally required approach for Schedule 3 controlled drugs under the Veterinary Medicines Regulations and the Misuse of Drugs Regulations 2001. In the UK, while standard POM-V prescriptions do not require an RCVS number, any prescription for a Schedule 2 or 3 controlled drug issued by a vet must include this number to be valid for dispensing.

Incorrect: Requiring the use of a standardized pink FP10PCD form is an approach used for human private prescriptions of Schedule 2 and 3 controlled drugs, but it does not apply to veterinary prescriptions, which are written on the vet’s own practice stationery. Allowing a six-month validity period is an approach that applies to standard POM-V medicines, but Schedule 3 controlled drugs are legally restricted to a 28-day validity period. Accepting a prescription from any EEA-registered prescriber is an approach that fails to account for the UK requirement that veterinary surgeons prescribing Schedule 2 or 3 controlled drugs must be registered with the RCVS and provide their specific registration number on the face of the prescription.

Takeaway: Veterinary prescriptions for Schedule 2 and 3 controlled drugs must include the prescriber’s RCVS registration number and are valid for only 28 days.

Correct: Confirm the patient’s consent to the substitution, ensure the supply meets all criteria specified in the active protocol, and notify the patient’s GP of the specific change made after the dispensing process is complete. Under the Human Medicines Regulations 2012, a Serious Shortage Protocol (SSP) provides the legal authority for a pharmacist to supply a different product than what is on the prescription without needing to refer back to the prescriber for a new script. However, the pharmacist must ensure the patient agrees to the alternative, strictly follow the specific instructions of that individual SSP, and fulfill the requirement to inform the prescriber that a supply under the protocol was made.

Incorrect: Contacting the prescribing physician to obtain a new, amended prescription before dispensing the alternative formulation is unnecessary and bypasses the legal efficiency provided by the SSP framework. Documenting the substitution only on the internal pharmacy PMR system is insufficient because the pharmacist has a professional and legal obligation to ensure the patient’s primary care record is updated via prescriber notification. Exercising professional discretion to substitute the medication with any clinically equivalent alternative available in stock is legally unsafe; a pharmacist can only substitute exactly what is permitted within the specific parameters of the active SSP issued by the Secretary of State.

Takeaway: Serious Shortage Protocols allow pharmacists to legally substitute medications without a new prescription, provided they adhere to the specific protocol requirements, obtain patient consent, and notify the prescriber of the change.

Correct: Under the Public Interest Disclosure Act 1998, a pharmacy staff member is protected when making a qualifying disclosure if they have a reasonable belief that a wrongdoing, such as a breach of a legal obligation or a threat to health and safety, is occurring. The disclosure must be made in the public interest. Reporting to the employer or a prescribed body, such as the General Pharmaceutical Council, ensures the individual is protected from unfair dismissal or detrimental treatment as a result of speaking up.

Incorrect: Limiting concerns to an internal grievance procedure is incorrect because grievances typically relate to an individual’s own employment contract rather than the public interest, and PIDA specifically allows for external disclosure to prescribed bodies. Waiting for absolute proof of harm is incorrect because the legal threshold is reasonable belief, not absolute certainty; delaying a report can compromise patient safety and may violate GPhC professional standards. Reporting a concern solely to resolve a personal contractual dispute is incorrect because the law requires the disclosure to be in the public interest to qualify for whistleblowing protection, and personal grievances are handled under different employment laws.

Takeaway: To qualify for legal protection under whistleblowing legislation, a disclosure must be based on a reasonable belief of wrongdoing and be made in the public interest.

Correct: Under the Human Medicines Regulations 2012, products registered under the Simplified Registration Scheme (HR) are prohibited from claiming any therapeutic indications. The statutory labeling must include the scientific name of the stock followed by the degree of dilution, the name and address of the registration holder, the expiry date, and the mandatory cautionary statement “homeopathic medicinal product without approved therapeutic indications”. This ensures the consumer is aware that the product has not been assessed for efficacy in treating specific conditions.

Incorrect: Including a therapeutic indication for minor conditions is only permitted for products registered under the National Rules Scheme (NR), not the Simplified Registration Scheme. Referencing a registration number with the prefix NR is incorrect for the Simplified Scheme, which uses the HR prefix. Requiring a detailed pharmacological mechanism of action is not a statutory requirement for homeopathic labeling in the UK, as these products are registered based on traditional use and high dilution rather than conventional pharmacological data.

Takeaway: Homeopathic medicines registered under the Simplified Scheme must be labeled as having no approved therapeutic indications and must identify the stock by its scientific name.

Correct: Include the name of the patient, the name and address of the supplying pharmacy, the date of dispensing, the name of the product, clear directions for use, and the mandatory cautionary phrase Keep out of the reach and sight of children. This approach is mandated by the Human Medicines Regulations 2012, which requires these specific particulars to be present on the label of any medicinal product dispensed against a prescription to ensure patient safety and regulatory compliance. The requirement for the child safety warning is a legal necessity on the dispensing label itself, regardless of whether the manufacturer has included similar wording on the original packaging.

Incorrect: Omitting the cautionary phrase about children because it is on the manufacturer’s box is a regulatory failure, as the law requires this specific wording on the dispensing label for all medicines dispensed against a prescription. Using the date the prescription was signed instead of the date of dispensing is incorrect because the dispensing date is required to provide an accurate record of when the medicine was actually supplied to the patient. Replacing the full pharmacy address with a GPhC registration number is insufficient, as the regulations explicitly require the name and address of the supplier to be present on the label for clear identification and contact purposes.

Takeaway: Legal compliance for dispensed medicines requires the inclusion of specific labeling particulars, including the dispensing date and the mandatory child safety warning, to meet Human Medicines Regulations 2012 standards.

Correct: Performing a prompt internal audit of all recent entries to identify the error, recording the correction via a marginal note or footnote while leaving the original entry intact, and informing the Controlled Drugs Accountable Officer (CDAO) if the loss is significant or unexplained. This approach adheres to the Misuse of Drugs Regulations 2001, which mandates that entries in the Controlled Drugs (CD) register must not be cancelled, obliterated, or altered. Using marginal notes ensures the audit trail remains transparent, while the CDAO is the designated statutory lead for overseeing CD governance and safety within a UK healthcare jurisdiction.

Incorrect: Updating the balance by striking through previous entries is a direct violation of the Misuse of Drugs Regulations 2001, which requires that original entries remain legible and unaltered. Suspending the register for a police Controlled Drug Liaison Officer (CDLO) inspection is an inappropriate first step for a routine balance discrepancy, as the CDAO is the primary regulatory contact for governance issues. Delaying the correction for seven days to monitor stock is unsafe and fails the legal requirement for the register to be an accurate record of the drugs currently held in the pharmacy.

Takeaway: Under UK law, CD register discrepancies must be corrected using marginal notes to preserve the original entry, with significant or unresolved losses reported to the CDAO.

Correct: Under the Misuse of Drugs Regulations 2001, when a pharmacist is presented with a prescription for a Schedule 2 or 3 Controlled Drug and does not know the prescriber, they must take reasonable steps to satisfy themselves that the prescriber is genuine. Utilizing the official register of the relevant regulatory body, such as the General Medical Council or Nursing and Midwifery Council, to confirm the prescriber’s registration status and ensuring the practice details provided are legitimate constitutes a robust and legally compliant validation process.

Incorrect: Relying solely on the professional appearance of a letterhead or the presence of a prescriber identification number is insufficient because these elements can be fabricated and do not constitute an independent verification of the prescriber’s current legal authority to practice. Accepting secondary documentation provided by the patient, such as a business card, is inappropriate as the pharmacist’s duty is to perform an independent check rather than relying on information mediated by the person requesting the drug. Cross-referencing against an internal database for similar names is unsafe and legally inadequate, as it fails to confirm the specific identity and current registration of the individual who signed the prescription presented.

Takeaway: Pharmacists have a legal and professional obligation to independently verify the identity and registration status of unknown prescribers when dispensing Schedule 2 and 3 Controlled Drugs.

Correct: Under the Human Medicines Regulations 2012 and professional standards set by the General Pharmaceutical Council (GPhC), supplementary prescribing is a voluntary partnership between an independent prescriber, a supplementary prescriber, and the patient. A Clinical Management Plan (CMP) is a mandatory legal requirement that must be in place before any prescribing occurs. The CMP must be patient-specific and include the specific conditions to be treated, the medicines that may be prescribed, and the circumstances in which the supplementary prescriber should refer back to the independent prescriber. Most importantly, the plan must be formally agreed upon by all three parties: the independent prescriber, the supplementary prescriber, and the patient.

Incorrect: Allowing a supplementary prescriber to initiate treatment for a new condition not listed in the Clinical Management Plan, even if they intend to inform the independent prescriber later, is a breach of the legal framework. Supplementary prescribers only have the authority to prescribe within the limits of the agreed CMP. Adjusting medication dosages beyond the specific ranges or parameters defined in the CMP based on external clinical guidelines is also prohibited; the CMP itself must be formally updated and re-signed by the independent prescriber before such changes can be implemented. Delegating the review or oversight of a CMP to another clinical pharmacist who is not the designated independent prescriber for that specific patient is legally invalid, as the independent prescriber retains primary responsibility for the diagnosis and the parameters of the plan.

Takeaway: A Clinical Management Plan is a legally required, patient-specific document that must be agreed upon by the independent prescriber, supplementary prescriber, and patient before any supplementary prescribing can take place.

Correct: Under the Human Medicines Regulations 2012, a pharmacy may supply small quantities of medicines to other healthcare providers without a Wholesale Dealer Authorisation (WDA(H)) only if the supply is occasional, made on a non-profit basis, and intended to meet the needs of an individual patient. In this scenario, the regular nature of the supply over six months and the addition of a handling fee to generate a margin mean the activity constitutes wholesale trading, necessitating a license from the Medicines and Healthcare products Regulatory Agency (MHRA).

Incorrect: Relying on a specific percentage of turnover, such as a 5% threshold, is a common misconception and does not provide a legal exemption if the transactions are regular and conducted for profit. While maintaining detailed records of batch numbers and expiry dates is a requirement for professional practice and Good Distribution Practice, it does not exempt a business from the legal requirement to hold a wholesale license when the criteria for exemption are not met. Restricting supplies to emergency medications for direct administration to patients does not bypass the licensing requirement if the commercial and frequency thresholds for wholesale distribution are reached.

Takeaway: A Wholesale Dealer Authorisation is required if medicine supplies to other entities are regular or conducted with the intention of making a profit.

Correct: Under the Human Medicines (Amendment) (No. 2) Regulations 2017, schools in the UK are permitted to purchase adrenaline auto-injectors (AAIs) from a pharmaceutical chemist for use in emergencies. The legal requirement for this supply is a written order, which must be signed by the headteacher or principal of the school. The order must specify the name of the school, the purpose for which the medicinal product is required (emergency use), and the total quantity required. This regulation applies to all schools, including local authority maintained, academies, and independent schools.

Incorrect: A requisition signed by a school nurse or a designated first aider is legally insufficient, as the legislation specifically requires the signature of the headteacher or principal to authorize the purchase. While a school’s allergy management policy is essential for internal governance, it is not a legal requirement for the pharmacist to review this policy or individual student care plans before making a supply under the 2017 amendment. Restricting supply only to state-funded institutions is incorrect, as the legislation extends the same rights to independent schools to ensure the safety of all pupils.

Takeaway: A legal supply of adrenaline auto-injectors to a school requires a written order signed specifically by the headteacher or principal stating the school name, purpose, and quantity.

Correct: Under the Human Medicines Regulations 2012 and the Misuse of Drugs Regulations 2001, prescriptions issued by an appropriate practitioner in an EEA state or Switzerland are generally legally valid in the UK. However, this recognition does not extend to Controlled Drugs in Schedules 1, 2, or 3. Since Pregabalin is classified as a Schedule 3 Controlled Drug in the UK, a pharmacist cannot legally dispense it against a prescription issued by a prescriber registered in an EEA country like Germany. The pharmacist must refuse the request and advise the patient to obtain a prescription from a UK-registered prescriber.

Incorrect: One approach suggests dispensing the medication if the prescription is written in English and contains the prescriber’s contact details. While these are standard requirements for the validity of an EEA prescription for a Prescription Only Medicine (POM), they do not override the specific legal prohibition regarding Schedule 3 Controlled Drugs. Another approach focuses on verifying the prescriber’s registration status and ensuring the prescription is within the 28-day validity period for Controlled Drugs. While verification is a professional duty, it does not make a Schedule 3 prescription from an EEA prescriber legal. A third approach suggests treating the document as a standard private prescription if the patient provides identification and the drug has a UK marketing authorization. This is incorrect because the legal barrier is the jurisdiction of the prescriber in relation to the specific schedule of the Controlled Drug, which cannot be bypassed by patient identification.

Takeaway: Prescriptions issued by EEA or Swiss healthcare professionals are not legally valid in the UK for Controlled Drugs listed in Schedules 1, 2, or 3.

Correct: Under the Mental Capacity Act 2005 and NICE guideline SC1, covert administration must only occur if the person lacks capacity, it is in their best interests, and a multidisciplinary team (MDT) meeting involving the prescriber, pharmacist, and family or advocate has reached a consensus and documented a clear, time-limited management plan. This ensures the process is transparent, legal, and the least restrictive option for the patient.

Incorrect: Seeking consent solely from a Lasting Power of Attorney or next of kin is insufficient because the legal framework requires a formal multidisciplinary best interests process to be followed and documented. Updating a care plan based only on a prescriber’s confirmation of clinical necessity is incorrect as it bypasses the mandatory capacity assessment and the collaborative MDT decision-making process required by law. Switching to liquid formulations to facilitate discreet administration without following the full legal framework for covert medication is a breach of professional ethics and the resident’s rights, as any hidden administration constitutes covert use regardless of the formulation.

Takeaway: Covert medication administration is a last resort that requires a documented capacity assessment and a formal multidisciplinary best interests decision in accordance with the Mental Capacity Act.

Correct: Under the Human Medicines Regulations 2012, a medicine must be classified as a Prescription Only Medicine (POM) if it is likely to present a danger to health even when used correctly if used without medical supervision, or if it is normally prescribed for parenteral administration. This ensures that potent or potentially hazardous treatments are only accessed following a clinical assessment by an appropriate prescriber to mitigate risks of toxicity or misuse.

Incorrect: Classifying a medicine based on high acquisition costs or specific storage requirements like cold chain management is incorrect because these are logistical and economic factors rather than safety-based legal criteria for POM status. While chronic conditions often involve POMs, the legal requirement for POM classification is based on the inherent danger of the drug or the need for medical supervision, not simply the duration of the condition or the need for adherence monitoring. Market presence in other jurisdictions or the status of a new chemical entity may influence the licensing process, but it does not serve as a primary legal criterion for determining the POM classification within the UK regulatory framework.

Takeaway: POM classification is primarily determined by the risk of danger to human health without medical supervision and the route of administration, specifically parenteral use.

Correct: Providing the patient with contact details for the appropriate health or social care provider and maintaining a record of the referral in the pharmacy’s clinical records if the pharmacist considers it clinically significant aligns with the NHS Terms of Service for the Signposting essential service. Under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations, pharmacies are required to provide information to patients about other providers of health and social care services when the pharmacy cannot provide a required service. The regulations specify that a record of the signposting must be maintained where the pharmacist deems the interaction to be clinically significant for the patient’s ongoing care.

Incorrect: Issuing a formal written referral specifically to a General Practitioner and storing it in the private prescription register is incorrect because signposting covers a broad range of health and social care providers, not just GPs, and the private prescription register is a statutory record for specific medications, not for clinical signposting interventions.

Directing a patient to a local service verbally and recording the interaction in a daily diary is insufficient because it fails to meet the professional standards for clinical record-keeping. While verbal advice is part of the service, the clinical record system is the appropriate place for documenting significant interventions to ensure continuity of care, rather than a general pharmacy diary.

Supplying a generic NHS information leaflet and obtaining a signed declaration from the patient is not a legal requirement under the Essential Services framework. While leaflets can be helpful, the service requires personalized information regarding the specific provider the patient needs, and there is no regulatory requirement for a patient to sign a declaration acknowledging they have been signposted.

Takeaway: The Signposting essential service requires pharmacists to provide specific provider information to patients and document the intervention in the pharmacy’s clinical records whenever the interaction is deemed clinically significant.

Correct: Reporting all suspected adverse reactions for a medicine marked with an inverted black triangle, regardless of the severity of the reaction. This aligns with MHRA requirements where medicines under intensive monitoring, identified by the black triangle symbol, require the reporting of all suspected adverse drug reactions (ADRs), both serious and non-serious, to help characterize the safety profile of the new product during its early years on the market.

Incorrect: Reporting only those suspected adverse reactions for established medicines that have not been previously listed in the Summary of Product Characteristics (SmPC) is incorrect because for established medicines, all serious suspected ADRs should be reported, even if the reaction is already well-documented. Delaying the submission of a Yellow Card report until a definitive causal link between the medicine and the reaction has been clinically proven is incorrect because the scheme relies on the reporter’s suspicion; waiting for absolute proof can delay the identification of important safety signals and is not a requirement for reporting. Limiting the reporting of suspected adverse reactions in children to only those medications that are being used outside of their licensed indications is incorrect because the MHRA guidelines specify that all suspected ADRs in children should be reported, regardless of whether the use is licensed, off-label, or for an established medicine.

Takeaway: Pharmacists must report all suspected adverse reactions for Black Triangle medicines and all serious reactions for established medicines to the MHRA to maintain effective pharmacovigilance.

Correct: Under the Poisons Act 1972 and the Control of Poisons and Explosives Precursors Regulations 2023, a pharmacist must inspect the purchaser’s original, valid Home Office license before supplying a regulated Part 1 poison. This license must include a photograph of the individual, which the pharmacist must verify against the person present. The transaction must be recorded in the Poisons Register, including the license number, the name and address of the purchaser, and the date of the sale.

Incorrect: Accepting a UK photocard driving license alongside a digital copy of a Home Office license is incorrect because the law requires the inspection of the original physical license which contains the holder’s photograph for direct comparison. Relying on employer-issued identification for professional accounts is insufficient for regulated poisons, as the specific individual making the purchase must hold and present their own valid Home Office license regardless of the business relationship. Using a passport to supplement a license that lacks a photograph is invalid because a legitimate Home Office license for regulated substances is required by law to include a photograph of the holder to facilitate identity verification at the point of sale.

Takeaway: For the sale of regulated poisons, the pharmacist must verify the purchaser’s identity by matching them to the photograph on their original, valid Home Office license and recording the specific license details in the poisons register.

Correct: Submitting the annual renewal fee and a formal declaration of fitness to practise through the online portal at least two months before the current registration expires, while ensuring all required revalidation records are submitted as part of the renewal process. Under General Pharmaceutical Council (GPhC) regulations in Great Britain, pharmacists must renew their registration annually. This process requires the registrant to pay the prescribed fee and make a professional declaration confirming they meet the standards for pharmacy professionals, including having appropriate indemnity insurance and being fit to practise. Furthermore, the submission of revalidation records (comprising four CPD entries, one peer discussion, and one reflective account) is a mandatory component of the annual renewal cycle to demonstrate ongoing competence.

Incorrect: The approach involving a 14-day window after expiry is incorrect because the GPhC does not provide a post-expiry grace period for standard renewal; failure to complete the process by the deadline results in a notice of intended removal from the register, which can lead to a lapse in the legal authority to practise. The approach suggesting revalidation is only for those selected for audit is incorrect because the submission of revalidation entries is a mandatory annual requirement for all pharmacists to remain on the register, regardless of whether their specific records are selected for a detailed quality assurance review. The approach of submitting the fitness to practise declaration separately via post for confidentiality is incorrect because the GPhC requires all parts of the renewal, including the declaration, to be completed through the secure online portal to ensure administrative accuracy and integrated processing of the registrant’s file.

Takeaway: Annual registration renewal requires the timely and simultaneous submission of the renewal fee, a fitness to practise declaration, and revalidation records via the regulator’s online portal.

Correct: Under the Human Medicines Regulations 2012, pharmacists are prohibited from providing an emergency supply of Schedule 1, 2, or 3 Controlled Drugs at the request of a patient, with the sole exception of Phenobarbital or Phenobarbital Sodium for the treatment of epilepsy. This specific exception exists to prevent life-threatening status epilepticus that could occur from sudden withdrawal. The pharmacist must still be satisfied that there is an immediate need and that the patient has been previously prescribed the medication.

Incorrect: Supplying Temazepam is prohibited because although it is a Schedule 3 Controlled Drug, it does not fall under the specific exception for epilepsy treatment. Supplying Methylphenidate is prohibited as it is a Schedule 2 Controlled Drug, and no Schedule 2 substances can be provided via emergency supply at the request of a patient regardless of the duration of supply. Supplying Gabapentin is prohibited because it is a Schedule 3 Controlled Drug and is not Phenobarbital; the general 30-day rule for emergency supplies of most POMs does not override the specific prohibition on Schedule 3 substances.

Takeaway: Phenobarbital is the only Schedule 3 Controlled Drug permitted for an emergency supply at the request of a patient, specifically for the treatment of epilepsy.

Correct: Confirming the clinical details on a Home Oxygen Order Form (HOOF), ensuring the form is sent directly to the designated regional oxygen service provider, and documenting the intervention within the pharmacy records. In the UK, the HOOF is the specific legal and administrative document required to trigger the Home Oxygen Service (HOS). Pharmacists optimize the process by ensuring the HOOF is correctly completed and directed to the contracted regional supplier rather than attempting to dispense the item through standard retail channels. This ensures the patient receives the correct equipment, such as concentrators or static cylinders, which are managed by specialized contractors under NHS agreements.

Incorrect: Requesting an FP10 prescription from the prescriber to be dispensed from the pharmacy own wholesale-procured medical gas cylinders is incorrect because home oxygen is a specialized service provided by regional contractors. Community pharmacies do not typically stock or dispense home oxygen for long-term use due to the specialized equipment and maintenance required. Advising the patient that the HOOF must be accompanied by a standard FP10 prescription for the equipment is incorrect because the HOOF is a standalone document that covers both the gas and the necessary delivery hardware. Transcribing the HOOF into the Electronic Prescription Service (EPS) is incorrect because the Home Oxygen Service operates through a distinct pathway where the HOOF is sent directly to the supplier to initiate the service, rather than being processed as a standard pharmacy claim.

Takeaway: The Home Oxygen Order Form (HOOF) is the essential legal and clinical document for initiating oxygen services in the UK and must be transmitted to regional contractors rather than being processed as a standard pharmacy prescription.